• Netarsudil (AR-13324): Predictive siRNA Codelivery in Nanopa

  2026-08-04

  Netarsudil (AR-13324) stands out as a Rho kinase inhibitor that uniquely enables predictive, high-efficiency siRNA codelivery in nanoparticle systems. This dual capability empowers translational cytoskeletal and gene regulation research, streamlining workflows for ocular and fibrotic disease models.

• KR-12 Peptide–Cu(II) Binding: Theoretical and Experimental I

  2026-08-04

  This study applies advanced quantum chemical and calorimetric methods to unravel how the KR-12 peptide, derived from human cathelicidin LL-37, binds Cu(II) ions. The findings clarify critical structural determinants of peptide–metal interactions, informing peptide engineering and bioconjugation strategies.

• Solving Lab Challenges with EZ Cap™ Firefly Luciferase mRNA

  2026-08-03

  This article addresses critical workflow and data reproducibility challenges in cell-based bioluminescent assays using Firefly Luciferase mRNA. It demonstrates how EZ Cap™ Firefly Luciferase mRNA (5-moUTP) (SKU R1013) from APExBIO delivers robust, consistent results through advanced mRNA design, improved stability, and reduced innate immune activation, grounding each scenario in practical, evidence-based best practices.

• V5 Epitope Tag Peptide (SKU A6005): Reliable Protein Tagging

  2026-08-03

  This article delivers evidence-based guidance on deploying the V5 Epitope Tag Peptide (SKU A6005) in cell viability, proliferation, and cytotoxicity assays. By addressing common experimental challenges through scenario-driven Q&A, it demonstrates how high-purity, well-characterized tags like SKU A6005 from APExBIO support reproducibility, sensitivity, and workflow efficiency in advanced protein detection workflows.

• PPT (Propyl Pyrazole Triol): Precision ERα Agonism in Resear

  2026-08-02

  PPT (Propyl Pyrazole Triol) empowers researchers to dissect estrogen receptor alpha signaling with unmatched selectivity. This article details optimized workflows, real-world troubleshooting, and cross-disciplinary applications—bridging molecular discovery with translational impact in oncology and reproductive biology.

• Coronavirus Macrodomains Prevent PARP-Mediated Antiviral Inh

  2026-08-01

  Grunewald et al. (2019) reveal that the coronavirus macrodomain is essential for counteracting the inhibitory effects of host poly (ADP-ribose) polymerases (PARPs) on viral replication and interferon (IFN) induction. By pinpointing PARP12 and PARP14 as key regulators in this process, the study advances our understanding of host–virus interactions and provides foundational insights for antiviral research leveraging PARP inhibition.

• MMP-2-Responsive Peptide Nanocarriers Enhance Breast Cancer

  2026-07-31

  This study introduces a self-assembling peptide drug delivery system responsive to matrix metalloproteinase 2 (MMP-2), enabling targeted and sustained release of chemotherapeutics in breast cancer. The innovation prolongs intratumoral drug retention, augments immunogenic cell death, and shows promise for improving antitumor efficacy while minimizing systemic toxicity.

• BOP Reagent in Advanced Peptide Synthesis for Prodrug Design

  2026-07-31

  BOP reagent streamlines robust amide and phenyl ester formation, making it a workhorse in peptide and prodrug workflows. This guide delivers actionable protocol enhancements and troubleshooting inspired by recent advances in targeted chemotherapy and natural product-based drug delivery.

• Gly-Gly-Phe-Gly (GGFG) Peptide: Elevating Bioconjugation Wor

  2026-07-30

  Gly-Gly-Phe-Gly (GGFG) peptide stands out as a versatile, high-purity linker for antibody-drug conjugate development and advanced bioconjugation chemistry. This guide details protocol enhancements, troubleshooting, and innovative insights from recent structural peptide research to help researchers optimize and future-proof their experimental strategies.

• Gly-Gly-Phe-Gly (GGFG) Peptide: Enabling Precision Drug Conj

  2026-07-30

  The GGFG peptide delivers unmatched flexibility and reliability as a spacer for drug conjugation and antibody-drug conjugate (ADC) development. Explore stepwise protocols, advanced troubleshooting, and new experimental strategies enabled by this high-purity APExBIO linker.

• PDI Inhibition Enhances Panobinostat Efficacy in Multiple My

  2026-07-29

  This study reveals that combining the PDI inhibitor LTI6426 with panobinostat significantly improves anti-myeloma activity in preclinical models, even at reduced panobinostat doses. These findings offer a promising strategy to mitigate toxicity in multiple myeloma treatment regimens by leveraging ER stress pathway modulation.

• GSK621: Precision AMPK Agonist for Metabolic Reprogramming

  2026-07-29

  Explore GSK621 as a potent AMPK agonist, uniquely positioned for advanced metabolic reprogramming and acute myeloid leukemia research. This article delivers a deep dive into signaling mechanisms, experimental nuances, and new translational insights.

• GGFG Peptide: Advancing Drug Conjugation for the Next Oncolo

  2026-07-28

  Explore how the Gly-Gly-Phe-Gly (GGFG) peptide empowers translational researchers to design flexible, high-precision drug conjugates, particularly in the evolving landscape of targeted oncology. Integrating new mechanistic insights from epigenetic therapies and advanced linker strategies, this article provides actionable guidance and strategic foresight for innovators in peptide engineering and antibody-drug conjugate (ADC) development.

• Doxycycline in Oncology: Mechanistic Insights for Advanced C

  2026-07-28

  Explore the multifaceted roles of Doxycycline as a tetracycline antibiotic and metalloproteinase inhibitor in cancer research. This article delivers unique, in-depth analysis of its mechanisms and implications for next-generation assay design.

• Quantifying Drug-Induced Fractional Killing via High-Through

  2026-07-27

  The reference study introduces a robust protocol for quantifying fractional killing of cancer cells by anti-cancer drugs using high-throughput microscopy. This approach enables comparative analysis across hundreds of conditions, facilitating deeper insights into drug response heterogeneity and informing experimental design in kinase inhibitor research.

7808 records 3/521 page Previous Next 12345 下5页 Last page